摘要
目的:探讨五酯胶囊对肾移植患者他克莫司(FK506)血药浓度的影响。方法:对实施同种异体肾移植并予以FK506为基础的免疫抑制治疗的患者进行回顾性分析。采用微粒子酶免疫法(MEIA)监测患者服用五酯胶囊前后FK506的血药浓度,记录FK506的给药剂量,观察肾移植术后免疫抑制的疗效、用药后的不良反应,以及用药对肾移植患者血常规的影响。结果:五酯胶囊用药前、后FK506的血药浓度比较差异有统计学意义(P<0.05)。五酯胶囊服用剂量增大1倍后,FK506血药浓度增加的幅度大于60%,平均为87.28%,增加幅度存在个体差异,且增加值与五酯胶囊给药剂量呈正相关。患者服用五酯胶囊后未出现急性排斥反应和严重肝功能损害,血常规与用药前比较差异无统计学意义。结论:为防止器官移植后的排斥反应,肾移植患者在同时应用FK506和五酯胶囊时,应考虑五酯胶囊对FK506血药浓度的影响。
OBJECTIVE： To explore the effects of Wuzhi capsules on blood concentration of tacrolimus （FK506） in renal trans- plantation recipients. METHODS： The allograft renal graft recipients who were treated with FKS06 were analyzed retrospectively. The blood concentrations of FK506 in the patients were monitored by MEIA method before and after medication. Drug dosage of FK506 was recorded and therapeutic efficacy of immunosuppression, ADR, the effects of medication on blood routine were ob- served. RESULTS： There was statistical significance in blood concentration of FKS06 before and after medication （P〈0.05）.The blood concentration of FKS06 increased by over 60% after dosage of Wuzhi capsules doubled, by 87.28% in average, and the drug showed great individual difference in growth rate. There was positive correlation between the increase of blood concentration of FK506 and the dosage of Wuzhi capsules. No acute reject reaction and severe hepatic function injury was found after medication; there was no statistical significance in blood routine before and after medication. CONCLUSIONS：To prevent the rejection reaction after transplant operation, effects of Wuzhi capsule on blood concentration of FK506 Should be considered when renal transplanta- tion patints received FKS06 and Wuzhi capsules.
出处
《中国药房》
CAS
CSCD
2013年第43期4095-4097,共3页
China Pharmacy
